|Systematic (IUPAC) name|
|(1S,5R,13R,17S)- 10,17-dihydroxy- 4-(prop-2-en-1-yl)- 12-oxa- 4-azapentacyclo [9.6.1.01,13.05,17.07,18] octadeca- 7(18),8,10-trien- 14-one|
|Endotracheal, nasally, IV, IM|
|Bioavailability||2% (Oral, 90% absorption but high first-pass metabolism)|
|Synonyms||17-allyl- 4,5α-epoxy- 3,14-dihydroxymorphinan- 6-one|
|(what is this?)|
Naloxone (INN, BAN, USAN) marketed under the trade name Narcan among others, is a pure opioid antagonist. Naloxone is a medication used to counter the effects of opioid especially in overdose. It will usually reverse the depression of the central nervous system, respiratory system, and hypotension. Naloxone may be combined with opioids that are taken by mouth to decrease the risk of their misuse.
Use may cause symptoms of opioid withdrawal including: agitation, nausea, vomiting, a fast heart rate and sweating among others. In those with previous heart disease further heart problems have occurred. It appears to be safe in pregnancy after having been taken by a limited number of women.
It was developed by Sankyo in the 1960s. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. In most developed countries, naloxone is required to be present whenever opiates or opioids are administered intravenously to combat accidental overdose.
- 1 Medical uses
- 2 Side effects
- 3 Special populations
- 4 Pharmacodynamics
- 5 Pharmacokinetics
- 6 Administration
- 7 Legal status
- 8 Prehospital access
- 9 Identification
- 10 Media
- 11 See also
- 12 References
- 13 External links
It is included as a part of emergency overdose response kits distributed to heroin and other opioid drug users, and this has been shown to reduce rates of deaths due to overdose. A prescription for naloxone is recommended if a person is on a high dose of opioid (>100 mg of morphine equivalence/day), is prescribed any dose of opioid accompanied by a benzodiazepine, or is suspected or known to use opioids nonmedically. Prescribing naloxone should be accompanied by standard education that includes preventing, identifying, and responding to an overdose; rescue breathing; and calling emergency services.
Preventing opioid abuse
Naloxone may be combined with a number of opioids including buprenorphine and pentazocine so that when taken orally just the opioid has an effect but if misused and injected or taken in large doses the naloxone blocks the effect of the opioid. This combination is used in an effort to prevent abuse.
While naloxone is still the standard treatment in emergency reversal of opioid overdose, its clinical use in the long-term treatment of opioid addiction is being increasingly superseded by naltrexone. Naltrexone is structurally similar, but has a slightly increased affinity for κ-opioid receptors over naloxone, can be administered orally, and has a longer duration of action.
In a meta-analysis of people with shock, including septic, cardiogenic, hemorrhagic, or spinal shock, those who received naloxone had improved blood flow. The authors of the meta-analysis recommend further study and randomized trials to determine the suitability of naloxone as a treatment for shock.
Naloxone is also experimentally used in the treatment for congenital insensitivity to pain with anhidrosis, an extremely rare disorder (one in 125 million) that renders one unable to feel pain, or differentiate temperatures.
Possible side effects include: change in mood, increased sweating, nausea, nervousness, restlessness, trembling, vomiting, allergic reactions such as rash or swelling, dizziness, fainting, fast or irregular pulse, flushing, headache, heart rhythm changes, seizures, sudden chest pain, and pulmonary edema.
Naloxone has been shown to block the action of pain-lowering endorphins which the body produces naturally. These endorphins likely operate on the same opioid receptors that naloxone blocks. Naloxone is capable of blocking a placebo pain-lowering response, both in clinical and experimental pain, if the placebo is administered together with a hidden or blind injection of naloxone. Other studies have found that placebo alone can activate the body's μ-opioid endorphin system, delivering pain relief via the same receptor mechanism as morphine.
Pregnancy and breast feeding
Naloxone is pregnancy category B or C in the United States. Studies in rodents given a daily maximum dose of 10 mg naloxone showed no harmful effects to the fetus, although human studies are lacking and the drug does cross the placenta, which may lead to the precipitation of withdrawal in the fetus. In this setting, further research is needed before safety can be assured, so naloxone should only be used during pregnancy if it is a medical necessity.
It is currently unknown if naloxone is excreted in breast milk.
Kidney and liver dysfunction
Currently, no established clinical trials have been conducted in patients with insufficient kidney function or liver disease, and as such, these patients should be monitored closely if naloxone is clinically indicated.
Naloxone has an extremely high affinity for μ-opioid receptors in the central nervous system (CNS). Naloxone is a μ-opioid receptor (MOR) competitive antagonist, and its rapid blockade of those receptors often produces rapid onset of withdrawal symptoms. Naloxone also has an antagonist action, though with a lower affinity, at κ- (KOR) and δ-opioid receptors (DOR). Unlike other opioid receptor antagonists, naloxone is essentially a pure antagonist with no agonist properties. If administered in the absence of concomitant opioid use, no functional pharmacological activity occurs (except the inability for the body to combat pain naturally), in contrast to direct opiate agonists, which elicit opiate withdrawal symptoms of both opiate-tolerant and opiate-naive patients. No evidence indicates the development of tolerance or dependence on naloxone. The mechanism of action is not completely understood, but studies suggest it functions to produce withdrawal symptoms by competing for opiate receptor sites within the CNS (a competitive antagonist, not a direct agonist), thereby preventing the action of both endogenous and xenobiotic opiates on these receptors without directly producing any effects itself.
The Ki affinity values of (−)-naloxone for the MOR, KOR, and DOR have been reported as 0.559 nM, 4.91 nM, and 36.5 nM, respectively, whereas for (+)-naloxone, 3,550 nM, 8,950 nM, and 122,000 nM, respectively, have been reported. As such, (−)-naloxone appears to be the active isomer. Moreover, these data suggest that naloxone binds to the MOR with approximately 9-fold greater affinity relative to the KOR and around 60-fold greater affinity relative to the DOR.
When administered parenterally, as is most common, naloxone has a rapid distribution throughout the body. The mean serum half life has been shown to range from 30 to 81 minutes, shorter than the average half life of some opiates necessitating repeat dosing if you must stop opioid receptors from triggering for an extended period, unnecessary in an emergency clinical sense. Naloxone is primarily metabolized by the liver. Its major metabolite is naloxone-3-glucuronide which is excreted in the urine.
Naloxone is most commonly injected intravenously for fastest action, which usually causes the drug to act within a minute, and last up to 45 minutes. It can also be administered via intramuscular or subcutaneous injection. Finally, a wedge device (nasal atomizer) attached to a syringe may be used to create a mist which delivers the drug to the nasal mucosa, although this solution is more common outside of clinical facilities.
The individual is closely monitored for signs of improvement in respiratory function and mental status. If minimal or no response is observed within 2–3 minutes dosing may be repeated every 2 minutes until the maximum dose of 10 mg has been reached. If there is no response at this time alternative diagnosis and treatment should be pursued. If patients do show a response they should remain under close monitoring as the effects of naloxone may wear off before those of the opioids and they may require repeat dosing at a later time.
Naloxone is used orally along with Oxycontin Controlled Release, and helps in reducing the constipation associated with opioids. Enteral administration of naloxone blocks opioid action at the intestinal receptor level, but has low systemic bioavailability due to marked hepatic first pass metabolism.
In March/April 2014, the US Food and Drug Administration (FDA) approved a hand-held automatic injector naloxone product that is pocket-sized. The approval process was fast-tracked as one initiative to reduce the death toll caused by opiate overdoses in the US. At the time of approval, an estimated 16,000 annual deaths were attributed to prescription opioid overdoses in the US.
In the US, naloxone is classified as a prescription medication, though it is not a controlled substance. While it is legal to prescribe naloxone in every state, dispensing the drug by medical professionals (including physicians or other licensed prescribers) at the point of service is subject to rules that vary by jurisdiction.
While paramedics have carried naloxone for decades, law enforcement officers in many jurisdictions including Massachusetts, New Jersey, New Mexico, New York, and Pennsylvania carry it in order to respond to opioid overdoses.
Laws in many states have been changed in recent years to allow wider distribution of naloxone. Several states have also moved to permit pharmacies to dispense the medication without the patient first seeing a physician or other non-pharmacist professional. Over 200 naloxone distribution programs utilize licensed prescribers to distribute the drug, often through the use of standing medication orders  whereby the medication is distributed under the medical authority of a physician or other prescriber.
Following the use of the nasal spray device by police officers on Staten Island in New York, an additional 20,000 police officers will begin carrying naloxone in mid-2014. The state's Office of the Attorney General will provide US$1.2 million to supply nearly 20,000 kits and Police Commissioner William Bratton said: "Naloxone gives individuals a second chance to get help".
A survey of US naloxone prescription programs in 2010 revealed that 21 out of 48 programs reported challenges in obtaining naloxone in the months leading up to the survey, due mainly to either cost increases that outstripped allocated funding, or the suppliers' inability to fill orders. The approximate cost of a 1 ml ampoule of naloxone in the US is estimated to be significantly higher than in most Western countries.
Projects of this type are under way in many North American cities. CDC estimates the US programs for drug users and their caregivers prescribing take-home doses of naloxone and training on its use are estimated to have prevented 10,000 opioid overdose deaths. Healthcare institution-based naloxone prescription programs have also helped reduce rates of opioid overdose in North Carolina, and have been replicated in the US military. Programs training police and fire personnel in opioid overdose response using naloxone have also shown promise in the US and effort is increasing to integrate opioid fatality prevention in the overall response to the overdose crisis. Pilot projects were also started in Scotland in 2006. Also in the UK, in December 2008, the Welsh Assembly government announced its intention to establish demonstration sites for take-home naloxone.
2013 documentary film Reach for Me: Fighting to End the American Drug Overdose Epidemic interviews people involved in naloxone programs aiming to bring naloxone available to opioid users and pain patients.
- C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. p. 1396. ISBN 978-0-412-46630-4.
- Sirohi S, Dighe SV, Madia PA, Yoburn BC (August 2009). "The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity". J. Pharmacol. Exp. Ther. 330 (2): 513–9. doi:10.1124/jpet.109.152678. PMC 2713087. PMID 19435929.
- "Naloxone Hydrochloride". The American Society of Health-System Pharmacists. Retrieved Jan 2, 2015.
- "Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Retrieved 22 April 2014.
- GB patent 939287, "New morphinone and codeinone derivatives and process for preparing the same", published 1963-10-09, assigned to Sankyo
- US patent 3254088, Mozes JL, Gardens K, Fishman J, "Morphine Derivative", published 1966-05-31, assigned to E.I. Du Pont De Nemours And Company
- "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
- Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S (2006). "Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths". J Addict Dis 25 (3): 89–96. doi:10.1300/J069v25n03_11. PMID 16956873.
- Lazarus P (2007). "Project Lazarus, Wilkes County, North Carolina: Policy Briefing Document Prepared for the North Carolina Medical Board in Advance of the Public Hearing Regarding Prescription Naloxone". Raleigh, NC.[page needed][verification needed]
- Bowman S, Eiserman J, Beletsky L, Stancliff S, Bruce RD (July 2013). "Reducing the health consequences of opioid addiction in primary care". Am. J. Med. 126 (7): 565–71. doi:10.1016/j.amjmed.2012.11.031. PMID 23664112.
- Orman, JS; Keating, GM (2009). "Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.". Drugs 69 (5): 577–607. doi:10.2165/00003495-200969050-00006. PMID 19368419.
- Boef, B; Poirier V; Gauvin F; Guerguerian AM; Roy C; Farrell CA; Lacroix J (2003). "Naloxone for shock.". Cochrane Database Syst Rev. (4): CD004443. doi:10.1002/14651858.CD004443. PMID 14584016.
- Niemann, JT. "Reversal of clonidine toxicity by naloxone". Retrieved 22 March 2015.
- "Naloxone Side Effects in Detail". Drugs.com. Retrieved 5 May 2015.
- Schwartz JA, Koenigsberg MD (November 1987). "Naloxone-induced pulmonary edema". Ann Emerg Med 16 (11): 1294–6. doi:10.1016/S0196-0644(87)80244-5. PMID 3662194.
- Sauro MD, Greenberg RP (February 2005). "Endogenous opiates and the placebo effect: a meta-analytic review". J Psychosom Res 58 (2): 115–20. doi:10.1016/j.jpsychores.2004.07.001. PMID 15820838.
- Nuri, Banister (24 August 2005). "Placebo effect explained? Study shows the brain’s own endorphins may be responsible". Journal of Young Investigators. Archived from the original on 15 December 2012. Retrieved 6 May 2015.
- Sobor, M; Timar, J., Riba, P., Kiraly, KP., (2013). "Behavioural studies during the gestational-lactation period in morphine treated rats". Neuropsychopharmacol Hung 15 (4): 239–251. PMID 24380965.
- "NALOXONE HYDROCHLORIDE injection, solution". Daily Med. Retrieved 21 April 2014.
- Codd EE, Shank RP, Schupsky JJ, Raffa RB (September 1995). "Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception". J. Pharmacol. Exp. Ther. 274 (3): 1263–70. PMID 7562497.
- Wolfe TR, Bernstone T (April 2004). "Intranasal drug delivery: an alternative to intravenous administration in selected emergency cases". J Emerg Nurs 30 (2): 141–7. doi:10.1016/j.jen.2004.01.006. PMID 15039670.
- Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K (January 2000). "Oral naloxone reverses opioid-associated constipation". Pain 84 (1): 105–9. doi:10.1016/S0304-3959(99)00185-2. PMID 10601678.
- Brady Dennis (3 April 2014). "FDA approves device to combat opioid drug overdose". The Washington Post. Retrieved 8 April 2014.
- 21 U.S.C.A. §§801-904; see e.g., LA Rev Stat. Ann. §40:964 (specifically excluding Naloxone from the schedule of controlled substances.)
- Donna Leinwand Leger (3 February 2014). "Police carry special drug to reverse heroin overdoses". USA Today. Retrieved 8 April 2014.
- "Pennsylvania governor signs heroin antidote law". Lehigh Valley Live. 2 October 2014. Retrieved 5 May 2015.
- Mark Wollacott (19 February 2015). "Narcan: Helping to Save Lives in Bucks County". Steps To Recovery. Retrieved 5 May 2015.
- Jeff Werner (16 February 2015). "Bucks County law enforcement officers hitting the streets with life-saving overdose drug". Bucks Local News. Retrieved 5 May 2015.
- Corey Davis. "Legal interventions to reduce overdose mortality: Naloxone access and overdose good samaritan laws" (PDF). Network for Public Health Law.
- Davis CS, Webb D, Burris SC (2013). "Changing Law from Barrier to Facilitator of Opioid Overdose Prevention". Journal of Law, Medicine and Ethics.
- Ryan Oftebro, "Kelley-Ross Pharmacy provides Take-Home Naloxone to prevent opioid overdose", Kelley-Ross, August 20, 2013
- Beletsky L, Burris SC, Kral AH (2009). "Closing Death's Door: Action Steps to Facilitate Emergency Opioid Drug Overdose Reversal in the United States". SSRN Electronic Journal. doi:10.2139/ssrn.1437163.
- Burris SC, Beletsky L, Castagna CA, Coyle C, Crowe C, McLaughlin JM (2009). "Stopping an Invisible Epidemic: Legal Issues in the Provision of Naloxone to Prevent Opioid Overdose". SSRN Electronic Journal. doi:10.2139/ssrn.1434381.
- Jessica Durando (27 May 2014). "NYPD officers to carry heroin antidote". USA Today. Retrieved 30 May 2014.
- "Community-Based Opioid Overdose Prevention Programs Providing Naloxone — United States, 2010". Centers for Disease Control and Prevention 61 (6): 101–5. December 2010. PMID 22337174.
- "OD Prevention Program Locator". Overdose Prevention Alliance. Retrieved 15 May 2012.
- Karissa Donkin (9 September 2012). "Toronto naloxone program reduces drug overdoses among addicts". The Toronto Star. Retrieved 5 May 2015.
- Albert S, Brason FW, Sanford CK, Dasgupta N, Graham J, Lovette B (June 2011). "Project Lazarus: community-based overdose prevention in rural North Carolina". Pain Med. 12 Suppl 2: S77–85. doi:10.1111/j.1526-4637.2011.01128.x. PMID 21668761.
- Beletsky L, Rich JD, Walley AY (November 2012). "Prevention of fatal opioid overdose". JAMA 308 (18): 1863–4. doi:10.1001/jama.2012.14205. PMC 3551246. PMID 23150005.
- Beletsky L, Moroz E. "The Quincy Police Department: Pioneering Naloxone Among First Responders.". Overdose Prevention Alliance. Retrieved 15 May 2012.
- Lavoie D (April 2012). "Naloxone: Drug-Overdose Antidote Is Put In Addicts' Hands". Huffington Post.
- Davis CS, Beletsky L (2009). "Bundling occupational safety with harm reduction information as a feasible method for improving police receptiveness to syringe access programs: evidence from three U.S. cities". Harm Reduct J 6 (1): 16. doi:10.1186/1477-7517-6-16. PMC 2716314. PMID 19602236.
- "2013 National drug control strategy" (PDF). 2013.
- "IHRA 21st International Conference Liverpool, 26th April 2010 - Introducing 'take home' Naloxone in Wales" (PDF). Retrieved 9 March 2011.
- Reach for Me: Fighting to End the American Drug Overdose Epidemic
- Chicago Recovery Alliance's naloxone distribution project
- Report on Naloxone and other opiate antidotes, by the International Programme on Chemical Safety